About Asher Biotherapeutics
Asher Biotherapeutics is a private company based in South San Francisco, California, incorporated in 2019 in Delaware. It has reported $163,489,965 raised in three offerings on Form D since September 2019. Its chief executive is Craig Gibbs.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Apr 3, 2024 | Apr 16, 2024 | $54,999,990fully sold | 16 | $3.4M | EquityRule 506(b) | Form D ↗ |
| Aug 20, 2021 | Sep 7, 2021 | $107,999,975fully sold | 22 | $4.9M | EquityRule 506(b) | Form D ↗ |
| Aug 19, 2019 | Sep 5, 2019 | $490,000of $3.0M target | 8 | $61,250 | EquityRule 506(b) | Form D ↗ |
| Total, three offerings | $163,489,965 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Asher Biotherapeutics's Form D filed Apr 16, 2024.
CG
Craig Gibbs
Chief Executive Officer and director
ID
Ivana Djuretic
Executive officer and director
JT
Jeffrey Tong
Director
Reid Huber
Director
Also a director at Synnovation Therapeutics and a partner, third rock ventures and director at Terremoto.
KE
Kyle Elrod
Executive officer
BD
Bob Deresiewicz
Director
ES
Elaine Sun
Director
AY
Andy Yeung
Executive officer
DS
Don O'Sullivan
Executive officer
IC
Ian Clark
Director
Earlier filings also listed Yik Andy Yeung (executive officer, last listed Sep 2021).